Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price suggests a potential upside of 172.73% from the stock’s current price. Separately, Needham & Company […]